About the Editor
Preface
Contributors to Volume II
Part 1. Antipsychotic polypharmacy
1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? Peter F. Buckley
2. Antipsychotic polypharmacy in USA. Anand K. Pandurangi, John Vernon
3. Antipsychotic polypharmacy in Czech Republic and in Ukraine. Viktor P. Samokhvalov, Oxana Samokhvalova, Viktoria A. Verbenko, Georgij N. Verbenko
4. Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice. Lucio Ghio, Werner Natta, Simona Gotelli, Luigi Ferrannini
5. Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? KH Yong, Norman Sartorius, Kang Sim
6. Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura
7. Clozapine combinations in treatment-resistant schizophrenia patients. Vladimir Lerner and Chanoch Miodownik
8. Metabolic syndrome and antipsychotic polypharmacy. Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, Hiroto Ito
Part 2. Polypharmacy for other psychiatric conditions
9. Evidence based combination therapy for bipolar disorder. Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, Konstantinos N. Fountoulakis
10. Antidepressant combination strategies for major depressive disorder. André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, Roger S. McIntyre
11. Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk. Arun V. Ravindran and Tricia L. da Silva
12. Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? Frederike Schirmbeck and Mathias Zink